Safety profile of lutetium-177 in patients with impaired renal function: A retrospective analysis of adverse events in mCRPC treatment. Dr. Saylani highlighted that Lutetium-177 vipivotide tetraxetan ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration ...

Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for ...

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan ... or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients ...

is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177 Lu) vipivotide tetraxetan injection), a targeted radioligand therapy for adult patients with ...

Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), providing access to all eligible patients in the province. Pluvicto™ is a targeted radioligand ...

About PluvictoTM PluvictoTM (lutetium (177Lu) vipivotide tetraxetan injection ... healthcare system and invests over $30 million in R&D yearly in the country. For more information visit ...

MONTREAL, Feb. 3, 2025 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, effective February 1, 2025, Nova Scotia is publicly funding Pluvicto™ (lutetium (177Lu) ...